Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Plant-Based supplement ease long COVID? new trial aims to find out

NCT ID NCT07397910

Symptom relief Sponsor: Universidad Católica San Antonio de Murcia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a natural supplement (made from orange, grapefruit, olive leaf, and other plant extracts) combined with a personalized exercise program can help people with long COVID. The trial will include 40 adults who still have symptoms like inflammation and fatigue at least 3 months after their COVID-19 infection. Researchers will measure changes in inflammation markers and symptom severity over 4 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement containing orange extract, apigenin, luteolin, yerba mate extract, grapefruit extract, and olive leaf extract
What this could lead to
If it works, this could point toward a safe, natural way to reduce long COVID symptoms and improve quality of life.
What could go wrong
This is a very small early trial with only 40 people, so results may not apply to everyone. The supplement is a mix of natural compounds, and its effects are not proven yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects of both sexes. * Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA. * Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness. * No history of sequelae from a severe acute illness. Exclusion Criteria: * Subjects with an underlying disease that explains the clinical manifestations. * Presence of chronic inflammatory diseases. * Subjects with acute infections. * Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment. * Excessive alcohol consumption. * Hypersensitivity or intolerance to any of the components of the study products. * Use of any nutraceutical or dietary supplement. * Severe or terminal illnesses. * Subjects with a body mass index (BMI) over 32. * Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 Motor Activity post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCAM HiTech, Sport & Health Innovation Hub

    Murcia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.